Stockpolly
Search
Delisting risk
OSRH · NASDAQ · Biotechnology

OSR (OSRH)

Combines cancer immunotherapies and regenerative biologics with Korean neurovascular-device distribution.

$0.1165
At close0.00 (0.00%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue00001−3111000
Cost of revenue000010110030
Gross profit00000−30000−20
01004−9354713
Research & development000000000000
010002154413
Selling & marketing000000050000
General & administrative010002104403
Other expenses00003−11200200
Operating income0−100−47−3−5−4−6−4−3
110001−80−1−102
Interest income110001000000
Interest expense000000000000
Other non-operating income0−1000−180110−2
Income before tax0000−38−11−5−4−8−4−1
Income tax expense00000100−1100
Net income from continuing operations0000−37−11−5−3−9−3−1
Net income0000−37−110−2−9−3−1
EPS, basic$0.01−$0.01−$0.01−$0.02−$0.83$1.47−$2.54$0.02−$0.71−$2.02−$0.77−$0.02
EPS, diluted$0.01−$0.01−$0.01−$0.02−$0.83$1.47−$2.54$0.02−$0.71−$2.02−$0.77−$0.22
Weighted average shares, basic976444444444
Weighted average shares, diluted976444444444
EBITDA0000−19−9−3−2−5−11
Depreciation & amortization000031222222
EBIT0000−38−11−5−4−7−4−1